Format

Send to

Choose Destination
Hepatol Int. 2017 Sep;11(5):440-445. doi: 10.1007/s12072-017-9809-y. Epub 2017 Jul 11.

A cinnamon-derived procyanidin type A compound inhibits hepatitis C virus cell entry.

Author information

1
Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
2
Université de Strasbourg, Strasbourg, France.
3
Association ORACLE, Centre d'Oncologie de Gentilly, Nancy, France.
4
Indus Biotech Pvt Ltd, Pune, India.
5
Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France. Thomas.Baumert@unistra.fr.
6
Université de Strasbourg, Strasbourg, France. Thomas.Baumert@unistra.fr.
7
Institut Hospitalo-Universitaire, Pôle Hépato-digestif, Hôpitaux Universitaires de Strasbourg, Strasbourg, France. Thomas.Baumert@unistra.fr.
8
Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France. c.moog@unistra.fr.
9
Université de Strasbourg, Strasbourg, France. c.moog@unistra.fr.
10
Inserm, U1109, Fédération de Médecine Translationnelle (FMTS), Strasbourg, France. c.moog@unistra.fr.

Abstract

BACKGROUND AND AIMS:

Chronic hepatitis C virus (HCV) infection is a major cause of liver disease worldwide. Although direct-acting antivirals can cure the large majority of treated patients, important limitations remain, including treatment failure and high costs precluding access to therapy in resource-limited settings. We report herein the anti-HCV effects of IND02, a procyanidin type A molecule, isolated and characterized from cinnamon.

METHODS AND RESULTS:

Using cellculture-derived HCV (HCVcc), HCV pseudoparticles (HCVpp), and subgenomic replicons, we demonstrated that IND02 markedly and dose-dependently inhibited HCV cell entry. Kinetic assays demonstrated that IND02 inhibits HCV entry most likely at a postbinding step. Experiments performed using primary human hepatocytes confirmed inhibition of HCV entry by IND02, demonstrating the functional impact in the most physiological cell-based system for studying HCV-host interactions.

CONCLUSIONS:

The natural compound IND02 exhibits potent HCV cell entry inhibition and provides a novel perspective for development of a low-cost antiviral for treatment of HCV infection.

KEYWORDS:

Antiviral; Hepatitis C; IND02; Infection; Liver

PMID:
28698985
DOI:
10.1007/s12072-017-9809-y
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center